

PROGRAM SCHEDULE

Friday, August 2nd, 2024

Morning Sessions

7:30am - 8:20am	<i>Continental Breakfast</i>
8:20am - 8:30am	<i>Welcome Remarks:</i>
	<i>Session 5: Alternative SUD Targets & Signaling</i> <i>Presider: Andrea Hohmann</i>
8:30am - 8:50am	Sergi Ferre NIDA Pharmacological Targeting of G Protein-Coupled Receptor Heteromers
8:50am - 9:10am	Wolfgang Sadee Ohio State University Ligand-Free Signaling of G Protein Coupled Receptors: Multiple Forms with Distinct Functions – Relevance to Opioid and Serotonergic Drug Design
9:10am - 9:30am	Christie Fowler University of California, Irvine Seeing Through the Smoke: Therapeutic Development of $\alpha 42\beta 23$ PAMs to Promote Nicotine Cessation.
9:30am - 9:50am	Jane Acri NIDA
9:50am - 10:00am	Konstantinos Plakas University of Pennsylvania Small-Molecule Non-antagonist Radiotracers for Positron Emission Tomography Imaging of the Mu Opioid Receptor.
10:00am - 10:30am	<i>Coffee Break</i>
10:30am -	<i>Session 6: Cannabinoids in SUD treatment</i> <i>Presider: Raymond Booth</i>
10:30am - 10:50am	Laura Bohn The Herbert Wertheim UF Scripps Institute
10:50am - 11:10am	Andrea Hohmann Indiana University Bloomington Drugs of Abuse and Respiratory Depression: Challenges and Therapeutic Opportunities
11:10am- 11:30am	Markos Georgiades Northeastern University Development Of Chiral Endocannabinoid Probes
11:30pm - 11:50pm	Sergiy Tyukhtenko Northeastern University Novel Allosteric Modulators for Monoacylglycerol Lipase: From Discovery to Mechanism of Action
11:50pm- 12:00pm	Antonio M. Reck University of Connecticut The Monoacylglycerol Lipase Inhibitor JZL184 Attenuates Opioid-Induced Hyperalgesia in Mice

All sessions take place on the 17th floor of East Village, Northeastern University

****Schedule is subject to change****

PROGRAM SCHEDULE

Friday, August 2nd, 2024

Afternoon Sessions

12:00pm- 12:10pm	Aaliyah S. Tyson University of Southern California Inverse Agonism via Inactive Kappa Opioid Receptor
12:10am 12:30pm	Jimit Raghav Klaus Miczek, Memorial Talk TUFTS University Preclinical Evaluation of AM6527, a Cannabinoid Receptor Neutral Antagonist For Alcohol Use Disorder.
12:30pm -2:00pm	<i>Lunch</i>
2:00pm -	<i>Session 7: New Methods & Developments</i> <i>Presider: Laura Bohn</i>
2:00pm - 2:20pm	Gerhard Wagner Harvard Medical School Proteomics of the Cytocapsular Tube
2:20pm - 2:40pm	Hideaki Yano Northeastern University Characterization Of CB1 Receptor Antagonists Against Superagonism Elicited By Synthetic Cannabinoid Receptor Agonists
2:40pm - 3:00pm	D. Craig Hopp NCCIH Natural Products and Pain: Research Opportunities at NCCIH.
3:00pm - 3:10pm	Juan L. Gomez National Institute on Drug Abuse Negative Feedback Neuromodulation: A Novel Cocaine-Sensitive Chemogenetic Receptor
3:10pm- 3:20pm	Manish K. Jain University of North Carolina at Chapel Hill Structural Insights into the Two Orphan Human G-protein Coupled Receptors, GPR3 and GPR12, Expressed in the Human Brain.
3:20pm – 3:30pm	Mark Anthony Leon Duque Harvard University Photo-Affinity and Metabolic Labeling Probes Based on the Opioid Alkaloids
3:30pm -4:00pm	<i>Coffee Break</i>
4:00pm -	<i>Session 8: Opioid SUD's</i> <i>Presider: Spiro Pavlopoulos</i>
4:00pm - 4:20pm	Susruta Majumdar Washington University School of Medicine in St. Louis Targeting Waters in the Mu Opioid Receptor Leads to Unique Receptor Trafficking and Efficacy Profile.
4:20pm - 4:40pm	Tom Prisinzano University of Kentucky Searching for Synthetic Opioid Rescue Agents: Identification of a Potent Opioid Agonist with Reduced Respiratory Depression.
4:40pm - 4:50pm	<i>Closing Remarks</i>